UPB Stock Forecast & Price Target

Upstream Bio is viewed positively because verekitug has produced strong Phase 2 efficacy across two validated respiratory settings, including a 79% rate of clinically meaningful nasal polyp improvement at Week 24 in CRSwNP versus 24% with placebo and a 56% reduction in annualized asthma exacerbations at 100 mg every 12 weeks. The company’s thesis is strengthened by differentiated dosing convenience, with quarterly subcutaneous administration matching or improving on approved TSLP biology while potentially offering a more durable profile than current monthly biologics. In addition, the ongoing Phase 2 COPD study, with more than 400 participants enrolled and about 60% enrolled through 1Q26, gives the stock multiple shots on goal in a large multi-billion-dollar market.

Upstream Bio is viewed negatively because its limited cash runway and the significant capital required to advance pivotal Phase 3 asthma and CRSwNP programs create meaningful financing risk, even though management expects cash to fund operations through 2027. Current resources are insufficient to carry both programs through completion, and the expectation of a capital raise in 2H27 following the COPD data readout implies greater dilution than previously assumed, while a higher 13% discount rate reflects elevated investor sentiment risk. Fundamentally, the company remains dependent on verekitug’s success in competitive CRSwNP, asthma, and COPD markets, where clinical, regulatory, and commercial setbacks could materially impair future growth and valuation.